Fetuin-A is Associated with Disease Severity and Exacerbation Frequency in Patients with COPD
- 28 December 2012
- journal article
- Published by Taylor & Francis in COPD: Journal of Chronic Obstructive Pulmonary Disease
- Vol. 10 (1) , 28-34
Abstract
Fetuin-A is a liver protein that may serve as an inhibitor of systemic inflammation in humans. In the present study we assessed the levels of fetuin-A in COPD patients in stable condition and on exacerbation in an attempt to evaluate it as a clinically relevant biomarker that may serve as predictor of exacerbations of COPD (ECOPD). One hundred COPD outpatients (GOLD stage I to IV) were enrolled in a tertiary University hospital and were submitted to a detailed evaluation, including pulmonary function testing, exercise capacity, quality of life and evaluation of the presence of metabolic syndrome and serum CRP. All patients were followed-up for 1 year, and 36 were re-evaluated at the onset of an ECOPD. Forty otherwise healthy smokers served as controls. Serum fetuin-A levels were reproducible at baseline, 6 and 12 months. COPD patients presented lower levels of fetuin compared to controls [394.5 (321.8–419.6) vs. 487.3 (441.0–548.0) mg/L, p < 0.001]. COPD patients with GOLD stage IV had lower fetuin-A levels compared to stages I-II and III (p < 0.05). Fetuin-A was significantly reduced at the onset of an ECOPD compared to baseline (p < 0.001) and the time to the first ECOPD significantly different between patients with high and low levels of fetuin-A [HR 2.163 (95%CI 1.104–4.238), p = 0.024). The results of the present study suggest that fetuin-A is a reproducible and clinically relevant biomarker in patients with COPD that may be useful in the identification of exacerbation-prone patients.Keywords
This publication has 36 references indexed in Scilit:
- Systemic Manifestations of COPDChest, 2011
- Systemic inflammation in chronic obstructive pulmonary disease: a population-based studyRespiratory Research, 2010
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- From COPD to chronic systemic inflammatory syndrome?The Lancet, 2007
- C-reactive Protein as a Predictor of Prognosis in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Systemic inflammation and mortality in chronic obstructive pulmonary diseaseThis paper is one of a selection of papers published in this Special Issue, entitled Young Investigators' Forum.Canadian Journal of Physiology and Pharmacology, 2007
- Systemic and Upper and Lower Airway Inflammation at Exacerbation of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysisThorax, 2004
- Systemic effects of chronic obstructive pulmonary diseaseEuropean Respiratory Journal, 2003
- Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax, 2002